Capella Series A Marks Medicxi's First Move
This article was originally published in Scrip
Capella Bioscience Ltd. has raised £11m in a series A round financed by Advent Life Sciences, Medicxi Ventures and Osage University Partners. The company was seed financed in 2015 with £500,000 from Advent and Index Ventures.
Register for our free email digests: